What is Glenmark Pharmaceuticals Ltd's market cap?

Glenmark Pharmaceuticals Ltd (GLENMARK) has a market capitalization of ₹60,645 Cr.

What sector is GLENMARK in?

Glenmark Pharmaceuticals Ltd operates in the Pharmaceuticals — Formulations & API sector.

What is GLENMARK's return on equity?

Glenmark Pharmaceuticals Ltd has a return on equity (ROE) of 0.0%.

Loading company...

Analyzing...

Glenmark Pharmaceuticals Ltd (GLENMARK) — Analysis, Financials, Intelligence | The Stock Filter

The Organism · Company Intelligence

Glenmark Pharmaceuticals Ltd

GLENMARK|BSE: 532296

Pharmaceuticals — Formulations & APIHealthcare & Life Scienceswww.glenmarkpharma.com

₹2,238.50

+₹33.35 (+1.51%)|MCap ₹60,645 Cr

As of 31 Jul 2026 (End of Day)

Promoter: 46.6%Div Yield: 0.22%

52W Low ₹0.0052W High ₹2,474.00

PE 49.0xMedian PE 18.4xPB 6.5x

Secular Currents

Theme Connections

Pharma CDMO Healthcare Access

About the Company

Profile

Glenmark Pharmaceuticals Ltd. is a holding company, which engages in the development, manufacture and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 15,556 full-time employees. The firm is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The firm also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The firm has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.

Intelligence Profile

TSF Score

62/100

The Vitals · Company Health

Health Indicators

Shenanigan Score

28Clean

Trust Score

X-Ray

Concerns

🟠Profit decliningBusiness

Watch

Nothing flagged for monitoring

Strengths

🟢Efficient capital deployment (ROCE: 16.2%)Business
🟢Low leverage (D/E: 0.00x)Business
🟢Consistent dividend payerOpportunity

The Numbers · Key Metrics

PE Ratio

49.0x

ROE

0.0%

Revenue Growth 3yr

9.4%

Debt/Equity

0.00x

₹58,969 Cr

The Narrator · StoryTel Intelligence

FY2026Pharmaceuticals — Formulations & APIProduct Sales ModelModel:Revenue = Volume of Drugs Sold × Average Selling Price (Domestic + Export)

Key Insight

“Operates in Pharmaceuticals — Formulations & API.”

The Revenue Story

₹16,983 Cr revenue.

Total Income₹17,443 Cr

Revenue₹16,983 Cr(97.4% of Total Income)

Other Income₹461 Cr(2.6% of Total Income)

The Cost Story

COGS 28.0%, employees 21.1%.

EBITDA₹5,033 Cr(27.6%)

Cogs₹4,747 Cr(26.0%)

Other Expenses₹4,085 Cr(22.4%)

Employee₹3,578 Cr(19.6%)

Depreciation₹573 Cr(3.1%)

Finance Costs₹209 Cr(1.1%)

0.2%EBITDA Margin

EBITDA

27.6%

Cogs

26.0%

Other Expenses

22.4%

Employee

19.6%

Depreciation

3.1%

Finance Costs

1.1%

Key Metrics

ROE

0.0%

vs median 10.3%

ROCE

16.2%

vs median 13.7%

Net Margin

0.0%

vs median 7.6%

EBITDA Margin

15.9%

vs median 15.4%

Debt To Equity

0.00x

vs median 0.15x

Rev Growth 3yr

9.4%

vs median 10.0%

EPS Growth 3yr

-100.0%

vs median 16.0%

Forward View · Management Guidance

FINANCIALQ3FY26— 1High Impact

“nine months of FY '26, Glenmark's consolidated revenue is at rupees 1 lakh 32,119 million as against rupees 1 lakh, $655,000,000, recording a Y o Y growth of 31.”

FINANCIALQ3FY26— 1High Impact

“YOY growth of 15.1%. For the nine months of FY '26, Glenmark's consolidated revenue is at rupees 1 lakh 32,119 million as against rupees 1 lakh, $655,000,000, recording a Y o Y growth of 31.”

GUIDANCEQ3FY26— 2High Impact

“we expect a strong finish to FY 'twenty six with a good growth particularly in The U.”

The Context · Where does it sit?

Sector Context

The Canopy · Sector KPIs

Sector KPIs

Pharmaceuticals — Formulations & API

KPI	Company	Sector Median
ROE	0.0%▼	10.3%
ROCE	16.2%▲	13.7%
Net Margin	0.0%▼	7.6%
EBITDA Margin	15.9%▲	15.4%
Debt To Equity	0.00x▼	0.15x
Rev Growth 3yr	9.4%▼	10.0%
EPS Growth 3yr	-100.0%▼	16.0%

The Market · What is the market saying?

Market Signals

The Antenna · Media Intelligence

Media Signal

Moderate Impact

7d-0.54→30d-0.54

Based on 4 articles (0 in last 7 days)

The Numbers · Show me the data

Financials

Revenue₹16,983 Cr

PBT₹1,985 Cr

EPS₹37.58

(₹ Cr)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	₹16,983 Cr +27.5%	₹13,322 Cr +12.8%	₹11,813 Cr -9.1%	₹12,990 Cr +5.6%	₹12,305 Cr +12.4%	₹10,944 Cr +2.8%	₹10,641 Cr +7.9%	₹9,865 Cr
Other Income	₹461 Cr +305.0%	₹114 Cr -86.5%	₹840 Cr +165.2%	₹317 Cr +90.1%	₹167 Cr +231.9%	₹50 Cr -68.5%	₹160 Cr -23.3%	₹208 Cr
Total Income	₹17,443 Cr +29.8%	₹13,435 Cr +6.2%	₹12,653 Cr -4.9%	₹13,307 Cr +6.7%	₹12,472 Cr +13.4%	₹10,994 Cr +1.8%	₹10,801 Cr +7.2%	₹10,074 Cr
COGS	₹4,747 Cr +9.1%	₹4,353 Cr -1.4%	₹4,413 Cr -2.7%	₹4,537 Cr +3.5%	₹4,385 Cr +18.6%	₹3,699 Cr +0.0%	₹3,699 Cr +10.0%	₹3,362 Cr
	₹13,192 Cr +13.1%	₹11,663 Cr -0.4%	₹11,716 Cr +0.4%	₹11,673 Cr +8.4%	₹10,769 Cr +11.5%	₹9,656 Cr -0.8%	₹9,737 Cr +8.9%	₹8,940 Cr
Profit Before Tax	₹1,985 Cr +41.8%	₹1,399 Cr	₹36 Cr -95.8%	₹868 Cr -39.7%	₹1,441 Cr +4.3%	₹1,382 Cr +26.1%	₹1,096 Cr -15.7%	₹1,301 Cr
Exceptional Items	(₹2,266 Cr) -507.8%	(₹373 Cr) +58.6%	(₹901 Cr) -17.6%	(₹766 Cr) -193.5%	(₹261 Cr) ↓ Decline	₹45 Cr +35.5%	₹33 Cr -80.3%	₹167 Cr
	₹623 Cr +76.9%	₹352 Cr -81.1%	₹1,867 Cr +280.3%	₹491 Cr +9.7%	₹448 Cr +8.5%	₹412 Cr +28.8%	₹320 Cr -14.8%	₹376 Cr
Net Profit	₹1,362 Cr +30.1%	₹1,047 Cr ↑ Recovery	(₹1,434 Cr) ↓ Decline	₹377 Cr -62.0%	₹994 Cr +2.4%	₹970 Cr +25.0%	₹776 Cr -16.1%	₹925 Cr
Profit (Owners)	₹1,060 Cr +1.3%	₹1,047 Cr ↑ Recovery	(₹1,502 Cr) ↓ Decline	₹377 Cr -59.9%	₹942 Cr -2.9%	₹970 Cr +25.0%	₹776 Cr -16.1%	₹925 Cr
Minority Interest	₹302 Cr	₹0.04 Cr -99.9%	₹68 Cr	₹0.00 Cr -100.0%	₹52 Cr	₹0.00 Cr	₹0.00 Cr	₹0.00 Cr
Other Comprehensive Income	₹414 Cr +545.4%	₹64 Cr ↑ Recovery	(₹66 Cr) ↓ Decline	₹154 Cr +100.4%	₹77 Cr -11.5%	₹87 Cr ↑ Recovery	(₹246 Cr) +40.8%	(₹415 Cr)
EPS	₹37.58	₹37.11	(₹53.22)	₹13.38	₹33.37	₹34.38	₹27.50	₹32.78
Diluted Shares	₹28 Cr	₹28 Cr	₹28 Cr	₹28 Cr	₹28 Cr	₹28 Cr	₹28 Cr	₹28 Cr